RAYNE ROUCE to Precursor Cell Lymphoblastic Leukemia-Lymphoma
This is a "connection" page, showing publications RAYNE ROUCE has written about Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Connection Strength
0.620
-
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2023 03 01; 108(3):747-760.
Score: 0.128
-
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2022 03 20; 40(9):945-955.
Score: 0.117
-
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 11 10; 4(21):5414-5424.
Score: 0.109
-
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
Score: 0.101
-
Ponatinib use in two pediatric patients with relapsed Ph?+?ALL with ABL1 kinase domain mutations. Pediatr Hematol Oncol. 2019 11; 36(8):514-519.
Score: 0.100
-
Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy. Clin Cancer Res. 2013 Sep 15; 19(18):5079-91.
Score: 0.065